Compare Applied Digital Corporation (APLD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Applied Digital Corporation vs Neurocrine Biosciences Inc — how do they compare? Applied Digital Corporation trades at $30.78 (market cap $8.90B), while Neurocrine Biosciences Inc trades at $179.72 (market cap $17.82B). The key difference: Neurocrine Biosciences Inc is far larger — about 2× Applied Digital Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.
| APLD | NBIX | |
|---|---|---|
Market Cap | $8.90B | $17.82B |
Sector | Technology | Health |
52-Week High | $49.65 | $180.55 |
52-Week Low | $9.18 | $123.10 |
Enterprise Value | $10.00B | $16.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Applied Digital (APLD) trades at $31.15, down 3.53% today, amid bearish technical signals despite unanimous analyst buy ratings. The company shows strong revenue growth with $144M in 2025 and $319M projected for 2026, but remains unprofitable with negative margins. Recent news highlights APLD's pivot to AI data centers with $36B in contracted lease value, though execution risks and customer concentration persist.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and heavy capital spending. Risks include customer concentration and debt load, but analyst consensus targets $76.67 suggest significant upside if execution improves.
Neurocrine Biosciences (NBIX) trades at $177.11, down 1.91% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical signal with moving averages supporting upward trends, while RSI levels indicate potential overbought conditions. Recent news highlights strong sales growth from Ingrezza and pipeline advancements, including the Soleno acquisition, reinforcing long-term growth prospects in neuroscience.
Outlook remains positive with a consensus price target of $194, offering ~9.5% upside. Key opportunities include expanding product portfolio and blockbuster drug performance, while risks involve pipeline execution and market volatility. The stock's high valuation multiples require sustained growth to justify current levels, but analyst sentiment is overwhelmingly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
